872511-34-7

Basic information

• Product Name: 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea
• Synonyms: 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea;NVP-BGJ398;BGJ 398;BGJ-398;BGJ398 (NVP-BGJ398);3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea NVP-BGJ398;NVP-BGJ398 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea;Urea, N'-(2,6-dichloro-3,5-dimethoxyphenyl)-N-[6-[[4-(4-ethyl-1-piperazinyl)phenyl]amino]-4-pyrimidinyl]-N-methyl-, methanesulfonate
• CAS NO: 872511-34-7
• Molecular Formula: C26H31Cl2N7O3
• Molecular Weight: 560.47544
• Product Categories: Inhibitor;Inhibitors
• Mol File: 872511-34-7.mol

Chemical Properties

• Boiling Point: 747.9±60.0 °C(Predicted)
• Appearance: /
• Density: 1.354
• Storage Temp.: -20°C
• Solubility: Soluble in DMSO (up to 5 mg/ml)
• PKA: 11.02±0.70(Predicted)
• Stability: Stable for 1 year from date of purchase as supplied. Solutions in DMSO may be stored at -20°C for up to 2 months.
• CAS DataBase Reference: 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea(872511-34-7)
• EPA Substance Registry System: 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea(872511-34-7)

Safety Data

• Hazardous Substances Data: 872511-34-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea is used as a therapeutic agent for the treatment of various cancers and diseases driven by the activation of FGFRs. Its potent and selective inhibition of the FGFR family makes it a valuable compound in targeted cancer therapy and the development of precision medicine.
Used in Research Applications:
In the research field, 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea serves as a valuable tool compound for studying the role of FGFRs in cellular processes and disease progression. It aids researchers in understanding the mechanisms of action and potential therapeutic targets within the FGFR signaling pathway.
Used in Mouse Model of Achondroplasia:
3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-[6-[[4-(4-ethylpiperazin-1-yl)phenyl]amino]pyrimidin-4-yl]-1-methylurea has been utilized in a mouse model of Achondroplasia, the most common form of dwarfism, to correct the pathological hallmarks of this condition. Its application in this context highlights its potential use in treating genetic disorders related to the FGFR family.

References

1) Guagnano?et al.?(2011),?Discovery of 3-(2,6-Dichloro-3,5-dimethoxyphenyl)-1-(6-{[4-(4-ethyl-1-piperazinyl)phenyl]amino}-4-pyrimidinyl)-1-methylurea (NVP-BGJ398),?a Potent and Selective Inhibitor of the Fibroblast Growth Factor Receptor Family of Receptor Tyrosine Kinase?; J. Med. Chem.?54?7066 2) Komla-Ebri?et al.?(2016),?Tyrosine kinase inhibitor NVP-BGJ398 functionally improves FGFR3-related dwarfism in mouse model; J. Clin. Invest.?126?1871

InChI:InChI=1S/C26H31Cl2N7O3/c1-5-34-10-12-35(13-11-34)18-8-6-17(7-9-18)31-21-15-22(30-16-29-21)33(2)26(36)32-25-23(27)19(37-3)14-20(38-4)24(25)28/h6-9,14-16H,5,10-13H2,1-4H3,(H,32,36)(H,29,30,31)

Upstream product

• 1310746-10-1 NVP-BGJ₃₉₈ phosphoric acid 
• 872511-32-5 2,4-dichloro-3-isocyanato-1,5-methoxy-4-methylbenzene 
• 872511-35-8 of N⁴-(4-(4-ethylpiperazin-1-yl)phenyl)-N⁶-methylpyrimidine-4,6-diamine 

Relevant articles and documents

CRYSTALLINE FORMS OF 3-(2,6-DICHLORO-3,5-DIMETHOXY-PHENYL)-1-{6-[4-(4-ETHYL-PIPERAZIN-1-YL)-PHENYLAMINO]-PYRIMIDIN-4-YL}-1-METHYL-UREA AND SALTS THEREOF.

The present technology provides novel anhydrous and hydrated crystalline forms of 3-(2,6-dichloro-3,5-dimethoxy-phenyl)-1-{6-[4-(4-ethyl-piperazin-1-yl)-phenylamino]-pyrimidin-4-yl}-1-methyl-urea, amorphous and anhydrous crystalline polymorphs of its mono

PYRIMIDINE UREA DERIVATIVES AS KINASE INHIBITORS

The invention relates to compounds of formula (I) wherein the substituents X1, R1, R2, R3 and R4 have the meaning as set forth and explained in the description of the invention, to processes for the preparation of these compounds, pharmaceutical compositions containing same, the use thereof optionally in combination with one or more other pharmaceutically active compounds for the therapy of a disease which responds to an inhibition of protein kinase activity, and a method for the treatment of such a disease.